Foamglas specified for pharma project
Pittsburgh Corning UK's Foamglas cellular glass insulation, pre-coated with the recently launched Terostat coating, has been installed by a major pharmaceutical manufacturer as part of a multi-million pound project to replace HCFC-based chillers, meeting the requirements of the Montreal Protocol.
Pittsburgh Corning UK's Foamglas cellular glass insulation, pre-coated with the recently launched Terostat coating, has been installed by a major pharmaceutical manufacturer as part of a multi-million pound project to replace HCFC-based chillers, meeting the requirements of the Montreal Protocol.
The project required that the insulation should be not only environmentally sound, but should also be installed quickly to meet a fast-track project with minimum plant shut-down. Foamglas pipe segments with an outer layer of Terostat were used throughout the installation. It was installed as a single layer, and the Terostat silane-modified polymer coating eliminated the need for cladding or a secondary coating.
Foamglas does not burn or give off smoke or toxic fumes, which was a key requirement of the project. It also remains effective for long-term operation at the required temperature of -46°C. Its 100% closed cell structure ensures that it is impermeable to moisture and expands or contracts much less than other insulation materials. Conventional foam insulation has been proven to lack stability when used cryogenically and also has to be used in two layers to combat contraction in such projects.